Ding F, et al. - In this meta-analysis, researchers determined the incidence and the relative risk (RR) of hand-foot skin reaction (HFSR) correlated with vascular endothelial growth factor receptor–tyrosine kinase inhibitors (VEGFR-TKIs). In total, 24,956 individuals from 57 studies have been involved. Data reported that the overall incidence of all-grade and high-grade HFSR related to VEGFR-TKIs, respectively, was 35.0% and 9.7%. It was noted that the use of VEGFR-TKIs significantly raised the risk of developing all-grade and high-grade HFSR. Subgroup analyses showed that the risk of HFSR was significantly increased depending on the type of tumor, VEGFR-TKI, trial phase, treatment regimen, and control therapy. In cancer patients receiving VEGFR-TKIs, high risk of HFSR is prone to develop. No evidence of bias in publication has been observed.